A Stepwise Plan for Late-Life Depression

Simple steps for better depression care in older adults

STUDY: Houix M et al, European Psychiatry 2026

STUDY TYPE: Expert consensus (four-round Delphi survey)

FUNDING:  Independent

Background

A group of 23 experts in geropsychiatry from France set out to build a practical, stepwise tool for prescribing antidepressants safely in adults over age 65.

First-Line Antidepressants

SSRIs, particularly sertraline, citalopram, or escitalopram, are recommended as first-line treatment for their safety profile and low drug interaction risk. Start at half the usual adult dose and increase gradually, aiming to reach a therapeutic dose within 4 to 12 weeks. Check sodium before starting, and again if the patient is on a thiazide diuretic or develops confusion or falls, since SSRI-related hyponatremia is a recurring concern throughout the tool.

Mirtazapine is a reasonable first-line alternative when appetite loss or insomnia is prominent.

Adjust doses for renal or hepatic impairment, for example, capping venlafaxine at 187.5 mg/day and avoiding duloxetine in severe renal insufficiency.

Dr. Aiken’s Take

That’s reasonable, and sertraline is also favorable in heart disease. However, I’d avoid citalopram given FDA-warnings about QTc and dose limitations. Bupropion may seem like a good choice in older adults, but it has a fall risk in older adults. Vortioxetine is well-studied in older adults and may improve cognition; it is recommended second line here, perhaps because it is expensive.

Second-Line Strategies

When there’s a partial response at an effective dose, the panel favors augmenting over switching: adding mirtazapine to an antidepressant, or, after two failed monotherapy trials, adding lithium or a low-dose atypical antipsychotic such as aripiprazole or quetiapine.

Tricyclics are not recommended as first-line treatment given their anticholinergic and cardiovascular burden; clomipramine is reserved as a last resort under hospital supervision (cardiac risks).

Electroconvulsive therapy is the standard for severe, psychotic, or treatment-resistant depression, with repetitive transcranial magnetic stimulation positioned as an earlier option when a patient can’t tolerate or refuses medication.

For higher levels of treatment resistance, consider pramipexole (if apathy/anhedonic), methylphenidate (if apathy/anhedonia), ketamine IV, or lamotrigine (they don’t specify when, but lamotrigine is not effective in unipolar depression except possibly in chronic cases).

Dr. Aiken’s Take

TMS has better evidence for safety and efficacy than pharmacologic augmentation, particularly in the elderly, but cost and accessibility get in the way. ProLivRx is an at-home neuromodulation device, and tDCS has evidence in vascular depression.

Mirtazapine augmentation failed in all its large trials, but worked in small trials. It’s a maybe, but has an edge in anxious depression and insomnia, so is reasonable to include here.

Aripiprazole is frequently endorsed for older adults because it succeeded (and looked tolerable) in a well-designed trial. However, that trial was too short to detect tardive dyskinesia, a which occurs around 5-7% per year after age 50. Quetiapine has broad efficacy — addressing depression, anxiety, and sleep — but a fall risk (this is lowered with XR form). Other antipsychotic risks that cause more concern in the elderly include EPS, anticholinergic, and temperature imbalance.

The guidelines miss light therapy, which is effective in older adults, particularly in Parkinson‘s and Dementia, and has a large effect size in seasonal and non-seasonal depression. They also miss l-methylfolate, and older age is a predictor of folate-related problems.

What About Psychotherapy?

These guidelines only addressed medications and neuromodulation. Psychotherapy, however, is an important part of treatment and there is evidence that older adults with depression respond better to this intervention.

Personalize vs Guidelines

Guidelines focus on a single disorder, but most patients have comorbidities that help us personalize the treatment. For example, 75% of patients with depression over age 70 have vascular depression, and this responds to unique approaches (and not antidepressants).